Wenzhou Medical Univ. OLIG2 compound B01

Wenzhou Medical Univ. OLIG2 compound B01: sourced facts only. name: "Among the synthesized compounds, B01 emerged as a potent and selective OLIG2 inhibitor, exhibiting strong anti-proliferative activity in U87 and U251 cells with IC50 values of 7.0 μM and 6.4 μM, respectively." [PMID:40763665]; target: "Among the synthesized compounds, B01 emerged as a potent and selective OLIG2 inhibitor, exhibiting strong anti-proliferative activity in U87 and U251 cells with IC50 values of 7.0 μM and 6.4 μM, respectively." [PMID:40763665]; developer: "School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China." [PMID:40763665]; stage: "In vivo, B01 reduced tumor volume by 46 % compared to control in a U87 xenograft model, with enhanced efficacy observed in combination therapy." [PMID:40763665]